Ivermectin and gynecologic cancer: What's the data?
Publication Title
Gynecol Oncol Rep
Document Type
Article
Publication Date
8-1-2025
Keywords
washington; swedish; swedish cancer; covid-19
Abstract
•Ivermectin is currently approved by the US Food and Drug Administration (FDA) in 1996 as an oral medication for intestinal strongyloidiasis and onchocerciasis.•The data on ivermectin as a gynecologic cancer-fighting compound is lacking.•Clinical studies on ivermectin use in cancer are limited to effects observed in cell lines.•We have not assessed ivermectin's safety and efficacy in gynecologic cancers.•We do not recommend and strongly caution the use of ivermectin in the treatment of gynecologic cancers.
Area of Special Interest
Cancer
Area of Special Interest
Women & Children
Specialty/Research Institute
Pharmacy
Specialty/Research Institute
Oncology
Specialty/Research Institute
Obstetrics & Gynecology
DOI
10.1016/j.gore.2025.101803
COinS
